Cindy J Rubin

Learn More
The efficacy and safety of muraglitazar versus glimepiride were evaluated in patients with type 2 diabetes. After open-label metformin monotherapy, 1,805 patients received randomised therapy with muraglitazar 2.5 mg or 5 mg or with glimepiride 1 mg in a double-blind 52-week study. The primary end point was change in glycosylated haemoglobin (HbA1C);(More)
BACKGROUND Many patients with type 2 diabetes mellitus (DM) with inadequate long-term blood glucose control with sulfonylurea or metformin monotherapy require additional treatment. The synergistic effects of combining glipizide with metformin on glucose control may be realized by treating the primary effects of type 2 DM, impaired insulin secretion, and(More)
Test Suite Design<lb>An abstract test suite (ATS) is a test specification document<lb>that describes tests to be carried out to ensure that a partic<lb>ular implementation conforms to a certain specification. The<lb>ATS consists of a collection of tests and the definition of the<lb>related components that are used for their specification. The<lb>basis of a(More)
In this trial we evaluated the efficacy and safety of muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, plus glyburide in patients with type 2 diabetes not controlled with sulphonylurea monotherapy. After 2 weeks of open-label glyburide (15 mg/day), 583 patients were randomised to additionally receive muraglitazar 2.5(More)
The Hewlett-Packard Journal is published bimonthly by the Hewlett-Packard Company to recognize technical contributions made by Hewlett-Packard (HP| personnel. While the information found in this publication is believed to be accurate, the Hewlett-Packard Company disclaims all warranties of merchantability and fitness for a particular purpose and all(More)
OBJECTIVE Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists can cause peripheral edema in susceptible individuals. To investigate the mechanistic basis underlying this adverse event, we performed a candidate gene analysis of patients enrolled in clinical trials of muraglitazar, an investigational PPARalpha/gamma dual agonist, and(More)
Muraglitazar is a dual (alpha/gamma) PPAR activator. Dual receptor activation may improve glycaemic and lipid profiles in patients with type 2 diabetes mellitus.This randomised double-blind trial in 1,477 drug-naive patients with type 2 diabetes compared the efficacy and safety of muraglitazar (0.5, 1.5, 5, 10, and 20 mg) with pioglitazone (15 mg).(More)
BACKGROUND Peroxisome proliferator-activated receptors (PPARs) present a therapeutic target, and simultaneous activation of PPAR-alpha and PPAR-gamma may provide improvements in glycemic control and dyslipidemia in patients with type 2 diabetes. OBJECTIVE The goal of this study was to evaluate the efficacy and safety of muraglitazar, a dual (alpha/gamma)(More)
OBJECTIVE We sought to evaluate the effects of muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor (PPAR) activator within the new glitazar class, on hyperglycemia and lipid abnormalities. RESEARCH DESIGN AND METHODS A double-blind, randomized, controlled trial was performed in 1,159 patients with type 2 diabetes inadequately(More)
  • 1